Axcella

85 articles with Axcella

• Axcella Reports First Quarter 2022 Financial Results and Provides Business Update

  5/5/2022

  Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, announced financial results for the first quarter ended March 31, 2022 and provided a business update.

• Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

  3/30/2022

  Axcella Therapeutics today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

• 

  Long COVID: New Insights Could Provide Treatment Options

  3/28/2022

  Although some may be hopeful that the end of the COVID-19 pandemic is nearby, millions still are facing their own lifelong version of the pandemic.

• Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022

  3/23/2022

  Axcella Therapeutics today announced that it plans to report its fourth quarter and year end 2021 financial results and other business updates on March 30, 2022.

• Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market

  3/16/2022

  Axcella Therapeutics today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 13,089,002 shares of common stock (the “Shares”) at a purchase price of $1.91 per share.

• Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH

  2/14/2022

  Axcella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.

• Axcella Therapeutics Announces Appointment of New Chief Financial Officer

  2/7/2022

  Axcella Therapeutics today announced the appointment of Robert Crane as the company’s new Chief Financial Officer.

• Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial

  12/16/2021

  Axcella Therapeutics today announced that patient screening is now underway in a Phase 2a trial that is investigating AXA1125, an oral product candidate, as a potential treatment for Long COVID, also known as Post COVID-19 Condition and post-acute sequelae of SARS-COV-2 infection (PASC).

• Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer

  12/6/2021

  Axcella Therapeutics today announced that Margaret Koziel, M.D., has been promoted to the role of Chief Medical Officer and added as a member of the company’s executive team.

• Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

  11/18/2021

  Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference.

• Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials

  11/10/2021

  Axcella Therapeutics today announced financial results for the third quarter ended September 30, 2021 and provided a business update.

• Axcella Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2021

  11/2/2021

  Axcella Therapeutics today announced two upcoming poster presentations at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually November 12-15, 2021.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.
• 

  Axcella Launches Long Covid Treatment Trial in the UK

  10/26/2021

  Axcella announced it is initiating a new clinical program to study AXA1125 in patients with Long Covid. The trial will be conducted at the Oxford Centre for Clinical Magnetic Resonance Research.

• Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021

  10/19/2021

  Axcella Therapeutics today announced that it will host a virtual R&D Day on Tuesday, October 26, 2021, at 10:00 a.m. ET.

• Axcella Announces Upcoming Investor Conference Presentation - Oct 05, 2021

  10/5/2021

  Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference.

• Axcella Announces Upcoming Investor Conference Presentation - Sep 07, 2021

  9/7/2021

  Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced that management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference.

• 

  Clinical Catch-Up: August 16-20

  8/23/2021

  It was another busy week in clinical trial news. Here’s a look.

• Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH

  8/16/2021

  Axcella today announced the publication of results from the company’s AXA1125-003 clinical study in The American Journal of Gastroenterology

• Axcella Reports Second Quarter Financial Results and Provides Business Update

  7/29/2021

  Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced financial results for the second quarter ended June 30, 2021 and provided a business update.